← Leaderboards
Gregory Kato
National Heart, Lung, And Blood Institute
$0
Attributed
$0
Total exposure
0
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding mix
By agency
—
By mechanism
—
Top collaborators
No co-investigators on record.
Most similar at National Heart, Lung, And Blood Institute
Same institution · by research overlap
Others in their field
Top investigators on “Sickle Cell Anemia”
- Russell E Ware · Duke University$48,435,687
- Michael Rutledge Debaun · Vanderbilt University Medical Center$38,268,866
- Martin H. Steinberg · Boston Medical Center$25,628,557
- Michael L. Terrin · Clinical Trials And Surveys Corporation$23,855,067
- Barbara L Kroner · Research Triangle Institute$21,141,016
- Garret A Fitzgerald · University Of Pennsylvania$20,602,198
Research focus
Sickle Cell AnemiaEnrollmentPulmonary HypertensionNitric OxideSickle CellAdultPlasmaPulmonary Artery StructureLungHemolysisResponsePublishingPharmaceutical PreparationsHydroxyureaHemoglobinDesignAffectErythrocytesSamplingData AnalysesBloodPressureProtocols DocumentationDose
Grant awards (71)
Development of Antisickling Drug Aes-103 in Patients with Sickle Cell Disease$387,760
ZIA · FY2014 · HL · contact PI
Therapeutic Application of Intravascular Nitrite for Sickle Cell Disease$376,355
ZIA · FY2014 · HL · contact PI
Natural History of Sickle Cell Disease and Other Hemolytic Disorders$376,355
ZIA · FY2014 · HL · contact PI
Development of Antisickling Drug Aes-103 in Patients with Sickle Cell Disease$470,922
ZIA · FY2013 · HL · contact PI
Natural History of Sickle Cell Disease and Other Hemolytic Disorders$227,335
ZIA · FY2013 · HL · contact PI
Plasma Biomarkers of Sickle Cell Pulmonary Hypertension$227,335
ZIA · FY2013 · HL · contact PI
Blood Studies of Endothelial Function and Systemic Inflammation$116,613
ZIA · FY2013 · HL · contact PI
Atorvastatin Therapy to Improve Endothelial Function in Sickle Cell Disease$50,181
ZIA · FY2013 · HL · contact PI
Pulmonary Hypertension and the Hypoxic Response in SCD (PUSH)$50,181
ZIA · FY2013 · HL · contact PI
Therapeutic Application of Intravascular Nitrite for Sickle Cell Disease$49,110
ZIA · FY2013 · HL · contact PI
Prevalence of PAH in SCD Patients in Nigeria$28,036
ZIA · FY2013 · HL · contact PI
Development of Antisickling Drug Aes-103 in Patients with Sickle Cell Disease$584,500
ZIA · FY2012 · HL · contact PI
Natural History of Sickle Cell Disease and Other Hemolytic Disorders$278,333
ZIA · FY2012 · HL · contact PI
Plasma Biomarkers of Sickle Cell Pulmonary Hypertension$278,333
ZIA · FY2012 · HL · contact PI
Cardiopulmonary Function Assessment and NO Based Therapies for SCD Pts with PAH$167,000
ZIA · FY2012 · HL · contact PI
Blood Studies of Endothelial Function and Systemic Inflammation$139,167
ZIA · FY2012 · HL · contact PI
Treatment of PH and SCD with Sildenafil Therapy$83,500
ZIA · FY2012 · HL · contact PI
Niacin Therapy to Improve Endothelial Function in SCD$83,500
ZIA · FY2012 · HL · contact PI
Multicenter Trial of NO for Acute Treatment of Sickle Cell Pain Episodes$55,667
ZIA · FY2012 · HL · contact PI
Atorvastatin Therapy to Improve Endothelial Function in Sickle Cell Disease$55,667
ZIA · FY2012 · HL · contact PI
Pulmonary Hypertension and the Hypoxic Response in SCD (PUSH)$55,667
ZIA · FY2012 · HL · contact PI
Nitric Oxide for Patients with Sickle Cell Anemia and Pulmonary Hypertension$55,667
ZIA · FY2012 · HL · contact PI
Use of Hydroxyurea & L-arginine or Sildenafil in Patients w/Sickle Cell Disease$27,833
ZIA · FY2012 · HL · contact PI
Synergy of Hydroxyurea and Erythropoietin on Fetal Hemoglobin in SCD$27,833
ZIA · FY2012 · HL · contact PI
Therapeutic Application of Intravascular Nitrite for Sickle Cell Disease$27,833
ZIA · FY2012 · HL · contact PI
Prevalence of PAH in SCD Patients in Nigeria$27,833
ZIA · FY2012 · HL · contact PI
Natural History of Sickle Cell Disease and Other Hemolytic Disorders$684,626
ZIA · FY2011 · HL · contact PI
Niacin Therapy to Improve Endothelial Function in SCD$297,663
ZIA · FY2011 · HL · contact PI
Treatment of PH and SCD with Sildenafil Therapy$148,832
ZIA · FY2011 · HL · contact PI
Blood Studies of Endothelial Function and Systemic Inflammation$148,832
ZIA · FY2011 · HL · contact PI
Cardiopulmonary Function Assessment and NO Based Therapies for SCD Pts with PAH$119,065
ZIA · FY2011 · HL · contact PI
Multicenter Trial of NO for Acute Treatment of Sickle Cell Pain Episodes$119,065
ZIA · FY2011 · HL · contact PI
Nitric Oxide for Patients with Sickle Cell Anemia and Pulmonary Hypertension$119,065
ZIA · FY2011 · HL · contact PI
Pulmonary Hypertension and the Hypoxic Response in SCD (PUSH)$119,065
ZIA · FY2011 · HL · contact PI
Atorvastatin Therapy to Improve Endothelial Function in Sickle Cell Disease$59,533
ZIA · FY2011 · HL · contact PI
Synergy of Hydroxyurea and Erythropoietin on Fetal Hemoglobin in SCD$29,766
ZIA · FY2011 · HL · contact PI
Prevalence of PAH in SCD Patients in Nigeria$29,766
ZIA · FY2011 · HL · contact PI
Systemic Nitrite Infusion and its Effect on Exercise Physiology and Metabolism$29,766
ZIA · FY2011 · HL · contact PI
Use of Hydroxyurea & L-arginine or Sildenafil in Patients w/Sickle Cell Disease$29,766
ZIA · FY2011 · HL · contact PI
Therapeutic Application of Intravascular Nitrite for Sickle Cell Disease$29,766
ZIA · FY2011 · HL · contact PI
Natural History of Sickle Cell Disease and Other Hemolytic Disorders$622,888
ZIA · FY2010 · HL · contact PI
Treatment of PH and SCD with Sildenafil Therapy$467,166
ZIA · FY2010 · HL · contact PI
Niacin Therapy to Improve Endothelial Function in SCD$342,588
ZIA · FY2010 · HL · contact PI
Pulmonary Hypertension and the Hypoxic Response in SCD (PUSH)$249,155
ZIA · FY2010 · HL · contact PI
Blood Studies of Endothelial Function and Systemic Inflammation$155,722
ZIA · FY2010 · HL · contact PI
Nitric Oxide for Patients with Sickle Cell Anemia and Pulmonary Hypertension$155,722
ZIA · FY2010 · HL · contact PI
Cardiopulmonary Function Assessment and NO Based Therapies for SCD Pts with PAH$124,578
ZIA · FY2010 · HL · contact PI
Multicenter Trial of NO for Acute Treatment of Sickle Cell Pain Episodes$62,289
ZIA · FY2010 · HL · contact PI
Atorvastatin Therapy to Improve Endothelial Function in Sickle Cell Disease$62,289
ZIA · FY2010 · HL · contact PI
Therapeutic Application of Intravascular Nitrite for Sickle Cell Disease$31,144
ZIA · FY2010 · HL · contact PI
Use of Hydroxyurea & L-arginine or Sildenafil in Patients w/Sickle Cell Disease$31,144
ZIA · FY2010 · HL · contact PI
Synergy of Hydroxyurea and Erythropoietin on Fetal Hemoglobin in SCD$31,144
ZIA · FY2010 · HL · contact PI
Systemic Nitrite Infusion and its Effect on Exercise Physiology and Metabolism$31,144
ZIA · FY2010 · HL · contact PI
Prevalence of PAH in SCD Patients in Nigeria$31,144
ZIA · FY2010 · HL · contact PI
Use of Bosentan in Patients with Symptomatic PH Associated with SCD$31,144
ZIA · FY2010 · HL · contact PI
Treatment of PH and SCD with Sildenafil Therapy$662,071
ZIA · FY2009 · HL · contact PI
Natural History of Sickle Cell Disease and Other Hemolytic Disorders$509,086
ZIA · FY2009 · HL · contact PI
Niacin Therapy to Improve Endothelial Function in SCD$359,355
ZIA · FY2009 · HL · contact PI
Multicenter Trial of NO for Acute Treatment of Sickle Cell Pain Episodes$209,624
ZIA · FY2009 · HL · contact PI
Pulmonary Hypertension and the Hypoxic Response in SCD (PUSH)$149,731
ZIA · FY2009 · HL · contact PI
Cardiopulmonary Function Assessment and NO Based Therapies for SCD Pts with PAH$119,785
ZIA · FY2009 · HL · contact PI
Blood Studies of Endothelial Function and Systemic Inflammation$119,785
ZIA · FY2009 · HL · contact PI
Systemic Nitrite Infusion and its Effect on Exercise Physiology and Metabolism$29,946
ZIA · FY2009 · HL · contact PI
Prevalence of PAH in SCD Patients in Nigeria$29,946
ZIA · FY2009 · HL · contact PI
Nitric Oxide for Patients with Sickle Cell Anemia and Pulmonary Hypertension$29,946
ZIA · FY2009 · HL · contact PI
Therapeutic Application of Intravascular Nitrite for Sickle Cell Disease$29,946
ZIA · FY2009 · HL · contact PI
Atorvastatin Therapy to Improve Endothelial Function in Sickle Cell Disease$29,946
ZIA · FY2009 · HL · contact PI
Use of Bosentan in Patients with Symptomatic PH Associated with SCD$29,946
ZIA · FY2009 · HL · contact PI
Use of Hydroxyurea & L-arginine or Sildenafil in Patients w/Sickle Cell Disease$29,946
ZIA · FY2009 · HL · contact PI
Synergy of Hydroxyurea and Erythropoietin on Fetal Hemoglobin in SCD$29,946
ZIA · FY2009 · HL · contact PI
Nitrite Infusion Studies on Healthy Volunteers$29,946
ZIA · FY2009 · HL · contact PI